ClinicalTrials.gg
CompletedNCT01111773Updated Mar 16, 2012

Study Evaluating a Heated Lidocaine and Tetracaine Topical Patch in the Treatment of Patients With Patellar Tendinopathy

A Phase 2 interventional study of Heated Lidocaine and Tetracaine Patch in Patellar Tendinopathy, sponsored by ZARS Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-16.

Sponsored by ZARS Pharma Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Tendinopathy with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Tendinopathy · United States.

Enrollment
71st of 89
13 · median 40
Started
2010
with 2 others
Phase 2
11 of 99
none open now
Registered
10th of 99
by date

Among the 99 studies in Tendinopathy with a site in United States, this one is the 71st largest by enrollment of the 89 interventional ones that give a count, is one of 3 that started in 2010, is one of 11 in phase 2, and was the 10th registered.

Tendinopathy

397 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

Browse Tendinopathy studies →

Open to participants now

15 of the 99 studies in Tendinopathy with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Tendinopathy studies recruiting now, 17 (36%) set no upper age limit and 23 (49%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Tendinopathy with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with patellar tendinopathy.

Read the detailed description

The purpose of this pilot study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with patellar tendinopathy. A number of efficacy variables will be employed to evaluate their utility for assessing painful responses in this population. The study will be a 2-week, open-label study conducted at a single study site in patients with pain associated with patellar tendinopathy in a single knee. During this out-patient study, patients will apply one study patch to the affected tendon twice daily for approximately 14 days. Patches will be applied morning and evening (applications separated by approximately 8-10 hours) and removed after 2-4 hours.

03

Conditions studied

  • Patellar Tendinopathy

Browse trials for

Keywords

  • Patellar tendonitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be at least 18 years of age
  • have pain associated with patellar tendinopathy in a single knee (minimum 2-week duration)
  • have tenderness at the proximal insertion of the patellar tendon in the affected knee

Exclusion criteria

Exclusion Criteria:

  • have any history of surgery in the target knee
  • have used any topically applied pain medication on the target treatment area within 3 days preceding the Screening/Baseline Visit
  • have had any injected in the target knee within 3 months of the Screening/Baseline Visit
  • have used any injected pain medication within 14 days preceding the Screening/Baseline Visit
  • are receiving class 1 antiarrhythmic drugs (ie, tocainide, mexiletine, etc.)

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Heated Lidocaine and Tetracaine Patch

    Drug: Heated Lidocaine and Tetracaine Patch

Interventions

  • DrugHeated Lidocaine and Tetracaine Patch

    Drug page: Lidocaine

    Patients will apply one lidocaine 70 mg and tetracaine 70 mg topical patch to the affected knee twice daily for approximately 14 days. Patches will be applied morning and evening (applications separated by approximately 8-10 hours).

    Also known as: Synera

06

What researchers measure

Primary outcomes

  1. Victorian Institute of Sport Assessment (VISA) score

    VISA questionnaire, an index of severity and symptoms of patellar tendinopathy, completed by the patient (beginning and end of the study).

    Time frame: Two weeks

Secondary outcomes

  1. Pain intensity

    Time frame: Two weeks

  2. Patient Global Assessment of Treatment Satisfaction (PGAS)

    Time frame: Two weeks

07

Study locations

1 site
  • Sports Medicine Clinic
    Warren, Michigan 48092, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Mar 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2010
First posted
Apr 28, 2010
Start
Jun 2010
Primary completionActual
Mar 2011
CompletionActual
May 2011
Results delay requested
Mar 14, 2012
Last update
Mar 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01111773
Lead sponsor
ZARS Pharma Inc.
Responsible party
Sponsor
First posted
Apr 28, 2010
Start date
Jun 2010
Primary completion
Mar 2011
Completion
May 2011
Last update
Mar 16, 2012

Study contacts

Henry Goitz, MD
principal investigator · Detroit Medical Center, Sports Medicine Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion